Barbiturates are still prescribed, but their role has narrowed dramatically since the 1970s, when benzodiazepines began replacing them as the go-to sedatives and sleep aids. Today, a handful of specific barbiturates remain in active clinical use for epilepsy, critical-care emergencies, headaches, neonatal seizures, and a few other niche applications. Their retreat from mainstream medicine is less about ineffectiveness than about a dangerously thin margin between a therapeutic dose and a lethal one, something newer drugs handle far more forgivingly.
Why Barbiturates Lost Their Dominance
For much of the twentieth century, barbiturates were the default pharmaceutical answer to anxiety, insomnia, and seizure disorders. That changed as safer alternatives arrived. Beginning in the 1970s, barbiturates were largely replaced by benzodiazepines, which work on the same broad brain system but are much harder to fatally overdose on when taken alone. The key difference comes down to how each drug class interacts with the brain’s main inhibitory signaling system. Both barbiturates and benzodiazepines bind to sites on the same receptor complex and enhance its calming effect, but barbiturates can directly open the receptor’s ion channel at high doses, essentially forcing the system into overdrive. Benzodiazepines cannot do this on their own; they only amplify the signal that is already there. That ceiling effect makes benzodiazepines far less likely to suppress breathing to a fatal degree.
The practical result was stark. Accidental overdoses, suicides, and severe dependence became strongly associated with barbiturate prescriptions. Barbiturate withdrawal can produce anxiety, tremors, seizures, psychosis, and in extreme cases death from circulatory collapse if not properly managed in a hospital setting. Physical dependence can develop after as little as a month of regular use at moderate doses. Those risks pushed regulators to restrict barbiturate scheduling, and physicians to reach for alternatives. In the United States, most barbiturates sit on Schedule II, III, or IV of the Controlled Substances Act, depending on the specific compound and formulation.
Epilepsy and Seizure Emergencies
The single largest remaining use of barbiturates in clinical medicine is for seizure control. Phenobarbital has been in continuous clinical use since 1912, making it one of the oldest anti-seizure drugs still prescribed. It remains widely used for neonatal and childhood seizures, and for drug-resistant forms of status epilepticus, a prolonged seizure emergency that can cause brain damage or death if not stopped quickly. Evidence suggests phenobarbital performs at least as well as lorazepam when used as a first-line treatment in early status epilepticus, and significantly better than valproic acid in cases where benzodiazepines have already failed. Data from randomized trials and large observational studies indicate it is well tolerated even at very high doses.
Despite this track record, phenobarbital has fallen out of favor in many parts of Europe and North America. Reports of side effects like low blood pressure, abnormal heart rhythms, and slowed breathing have made clinicians cautious, though the evidence for these complications at therapeutic doses appears less alarming than the drug’s reputation suggests. A 2023 review in the epilepsy literature argued that phenobarbital should be considered a “highly cost-effective treatment for early and established status epilepticus,” noting that its strong anti-seizure action comes with “remarkably little sedation” at appropriate doses. The disconnect between the evidence and the drug’s fading popularity is a recurring theme in neurology discussions about barbiturates.
Neonatal Seizures
One population where phenobarbital has held its ground more firmly is newborns. It remains the first-line treatment for neonatal seizures, particularly in babies with hypoxic ischemic encephalopathy, a condition caused by oxygen deprivation around the time of birth. Roughly 40 percent of these infants develop clinical seizures. In a randomized controlled trial comparing phenobarbital-treated neonates to a control group, only 8 percent of babies receiving the drug developed seizures, compared to 40 percent in the untreated group. The drug was well tolerated and did not increase the need for breathing support.
Treating newborns with phenobarbital does require careful attention to dosing, especially when the baby is also being cooled as part of therapeutic hypothermia, a common treatment for brain injury at birth. Cooling slows the baby’s metabolism, which means the drug lingers in the bloodstream longer. Studies have found that the drug’s half-life in cooled newborns can stretch considerably beyond what is seen in normothermic infants. Still, standard initial dosing appears to be appropriate, with adjustments made based on blood-level monitoring.
Headache Treatment
If you have ever been prescribed Fioricet or Fiorinal for a bad headache, you have taken a barbiturate. Butalbital, a short-acting barbiturate, is a component of several combination medications commonly prescribed for tension-type headache in the United States. It is paired with acetaminophen or aspirin and often caffeine. These prescriptions remain surprisingly common despite the fact that clinical guidelines discourage their use. The concern is not that they do not work for acute headaches; the concern is that frequent use can lead to medication overuse headache, a vicious cycle where the headache treatment itself begins causing more headaches.
Butalbital-containing medications occupy an odd space in American prescribing. They are rarely recommended in Europe and are not widely available outside the U.S. and Canada. Many headache specialists consider them outdated and would prefer to see patients treated with triptans, NSAIDs, or newer options like gepants. Yet prescriptions persist, partly because patients who have used them for years feel they work and resist switching, and partly because they are inexpensive and familiar. The barbiturate component adds a mild sedative and muscle-relaxing effect that some patients find helpful during a headache episode, even if the scientific rationale for including it is thin.
Critical Care and Brain Injuries
In intensive care units, barbiturates have a role that no other drug class has fully replaced: controlling dangerously high intracranial pressure after traumatic brain injury. When standard treatments fail to bring down pressure inside the skull, barbiturate coma, typically induced with thiopental or pentobarbital, is sometimes used as a last-resort measure. The drugs suppress brain activity so thoroughly that metabolic demand plummets, which can break the cycle of swelling and pressure.
A randomized trial comparing thiopental to pentobarbital for refractory intracranial hypertension found that thiopental appeared more effective at controlling the problem, though the study had limitations in how evenly the two groups were matched. In a separate study, methohexital, another barbiturate, lowered intracranial pressure significantly in survivors of severe brain injury within the first 24 hours. The side-effect profile during barbiturate coma is serious, including low blood pressure and suppressed immune function, but by the time clinicians reach for this option, the alternative is often brain herniation and death. It is a blunt instrument, but in the right circumstances, it saves lives.
Barbiturates in Global Health
The story of barbiturate prescribing looks very different depending on where you are in the world. In wealthy countries, phenobarbital is one option among many for epilepsy, and often not the first choice. In low- and middle-income countries, it may be the only anti-seizure medication available and affordable. Phenobarbital appears on the World Health Organization’s Model List of Essential Medicines for precisely this reason: it is effective, inexpensive to manufacture, and can be stored without refrigeration.
A survey of antiepileptic drug availability across 46 countries found that generic phenobarbital had the highest private-sector availability of any oral anti-seizure medicine, at nearly 70 percent. By contrast, newer drugs were far less accessible. Surveys in countries like Bhutan have examined whether phenobarbital supplies are sufficient to meet local needs, reflecting its ongoing importance in settings where the epilepsy treatment gap, the proportion of people with epilepsy who receive no treatment, remains enormous. For tens of millions of people worldwide, the question is not whether barbiturates are still prescribed but whether they are available at all.
Psychiatric Uses
One of the more unusual surviving applications of barbiturates is the amobarbital interview, sometimes called the “Amytal interview” after a brand name. In this procedure, a slow intravenous infusion of amobarbital is used to help evaluate and treat patients in certain psychiatric emergencies, including catatonia, hysterical stupor, and unexplained muteness. The drug can help differentiate between depressive, schizophrenic, and organic causes of unresponsiveness.
A controlled trial found that six of ten catatonic patients responded to amobarbital infusion, while none of ten responded to saline placebo. Four of the saline nonresponders then responded when given the actual drug. Response was typically visible within four minutes. The procedure is uncommon today, but it has not disappeared entirely. It remains a recognized diagnostic and therapeutic tool in psychiatric emergency settings, particularly for catatonia that does not respond to benzodiazepines. Some clinicians view it as an underused option given how effective it can be in the right situation.
End-of-Life and Assisted Dying
Outside the traditional medical context, barbiturates play a significant role in medically assisted death. In jurisdictions where physician-assisted suicide or medical assistance in dying (MAiD) is legal, high-dose barbiturates are among the most commonly used lethal agents. Pentobarbital and secobarbital are the two drugs most frequently chosen for oral self-administration. They are recommended by both the Netherlands’ euthanasia guidelines and the Canadian Association of MAiD Assessors and Providers’ oral medication protocol. The Netherlands has the most experience worldwide with oral assisted dying, and barbiturates have emerged as the most common, effective, and tolerable agents for patients choosing this option.
This use creates an unusual regulatory tension. The same drugs that are tightly controlled because of their overdose potential are deliberately prescribed in lethal doses for end-of-life purposes. In the United States, the rising cost and periodic unavailability of secobarbital has pushed some aid-in-dying programs to develop alternative drug cocktails, though barbiturates remain the gold standard when available. The veterinary world, meanwhile, uses pentobarbital routinely for animal euthanasia, which is a far larger volume of use than any human medical application at this point.
Why They Are Considered Inappropriate for Older Adults
One group for whom barbiturate prescriptions are particularly discouraged is older adults. The Beers Criteria, an influential list of medications considered potentially inappropriate for people over 65, flags all barbiturates except phenobarbital used for seizure control. The panel’s reasoning is straightforward: barbiturates are highly addictive and cause more adverse effects than most other sedative or hypnotic drugs in elderly patients. Older adults metabolize these drugs more slowly, increasing the risk of excessive sedation, falls, confusion, and respiratory depression. The Beers Criteria have been widely adopted by geriatricians and pharmacists as a screening tool, and their inclusion of barbiturates has contributed to the decline in prescribing among this population.
Despite this guidance, some older patients remain on long-term barbiturate prescriptions, often butalbital-containing headache medications carried forward from years or decades earlier. Abruptly stopping these drugs is risky because of the withdrawal danger, so physicians sometimes face the dilemma of continuing a medication they would never start today, or undertaking a careful, medically supervised taper.
Drug Interactions and Enzyme Induction
A practical concern that makes barbiturates inconvenient in modern medicine is their powerful effect on drug metabolism. Phenobarbital is one of the strongest known inducers of liver enzymes, particularly a family of enzymes responsible for breaking down a wide range of other drugs. Studies have shown that phenobarbital increases the activity of several enzyme subtypes, meaning that other medications taken alongside it may be cleared from the body faster than expected. This can reduce the effectiveness of oral contraceptives, blood thinners, HIV medications, certain cancer treatments, and many other drugs. For patients taking multiple medications, which describes most people with chronic conditions, this enzyme-induction effect creates a cascade of dosing problems that newer anti-seizure drugs largely avoid.
Sleep Effects and Why Barbiturates Are No Longer Sleep Aids
Barbiturates were originally the most popular prescription sleeping pills, and they do reliably make people fall asleep faster. But sleep research revealed a significant problem. A classic study published in the British Medical Journal found that while barbiturates shortened the time to fall asleep and increased total sleep duration, they also delayed and suppressed REM sleep, the phase associated with dreaming and memory consolidation. After about five nights, tolerance developed to the REM-suppressing effect, meaning users needed higher doses to get the same sedation while still disrupting their natural sleep architecture. When the drug was stopped, REM sleep came flooding back in excess, producing vivid, often disturbing dreams and fragmented sleep. This rebound insomnia drove many patients to keep taking the drug, fueling dependence.
Modern sleep medicine views barbiturate hypnotics as unsuitable for treating insomnia. Even benzodiazepines, which also affect sleep architecture, are now considered second-line to newer agents for most patients with chronic insomnia. Barbiturates sit several rungs further down the ladder, prescribed for sleep essentially never in current practice.
Illicit and Non-Medical Use
Although barbiturate abuse has declined enormously since the mid-twentieth century, it has not vanished. Pentobarbital in particular has attracted attention from drug monitoring programs. A 2024 report from the National Drug Early Warning System noted pentobarbital’s limited medical use in humans alongside its widespread availability in veterinary settings, where it is the standard euthanasia agent for companion animals. This veterinary supply chain creates a diversion pathway. Illicitly obtained pentobarbital has been linked to self-harm and to online communities that discuss lethal methods. Monitoring efforts focus on tracking whether veterinary-grade pentobarbital is reaching human users through theft, diversion, or international purchase.
Butalbital-containing headache medications are another source of non-medical barbiturate exposure. Because these drugs combine a barbiturate with caffeine, acetaminophen, or aspirin, their abuse potential is sometimes underestimated. Patients may escalate their use gradually, developing physical dependence without realizing it. Withdrawal from butalbital can mirror withdrawal from other barbiturates, with symptoms appearing within two to four days of stopping and potentially progressing to seizures if untreated. Case reports in the medical literature have documented full barbiturate withdrawal syndrome triggered by the abuse of headache medications alone.
The Amobarbital Interview in Forensic and Diagnostic Contexts
Beyond its psychiatric emergency use, the amobarbital interview has had a complicated relationship with forensic settings. In the mid-twentieth century, it was sometimes used as a so-called “truth serum,” administered to suspects or witnesses in the hope that a sedated person would be less able to lie. This application has been thoroughly discredited. People under the influence of amobarbital are more suggestible, not more truthful, and statements made during drug-induced sedation are generally inadmissible in court. The legitimate diagnostic use of the drug in psychiatry, distinguishing between organic and functional causes of unresponsiveness, should not be confused with these discredited forensic applications. The two purposes share a drug but not a scientific basis.
A related procedure, the Wada test, uses a brief injection of amobarbital (or increasingly, other agents) into one of the brain’s main arterial branches to temporarily anesthetize half the brain. This helps neurosurgeons map which hemisphere controls language and memory before epilepsy surgery. While alternatives like functional MRI are gradually replacing the Wada test in many centers, it remains in use, particularly when non-invasive mapping results are ambiguous.